Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith Miller

Showing results (141-150 of 154) with videos related to

Pageof 16
Sort By:
Bioorganic & Medicinal Chemistry Letters|February 12, 2008
2-Aminotetralones: novel inhibitors of MurA and MurZColin J Dunsmore, Keith Miller, Katy L Blake, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry BiomarkersCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 11, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC LaboratoriesEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in ImmunohistochemistryCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Ebiomedicine|September 13, 2025
New standards in HER2-low testing: the CASI-01 comparative methods studyDavid J Dabbs, Emina Torlakovic, Søren Nielsen, et al.
American Journal of Cancer Research|September 2, 2015
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplificationMatteo Brunelli, Alessia Nottegar, Giuseppe Bogina, et al.
Pageof 16

Showing results (141-150 of 154) with videos related to

Sort By:
Pageof 16
Bioorganic & Medicinal Chemistry Letters|February 12, 2008
2-Aminotetralones: novel inhibitors of MurA and MurZColin J Dunsmore, Keith Miller, Katy L Blake, et al.
Journal of Cancer Research and Clinical Oncology|July 30, 2013
The identification of a small but significant subset of patients still targetable with anti-HER2 inhibitors when affected by triple negative breast carcinomaEleonora Brunello, Giuseppe Bogina, Emilio Bria, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 10, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine - Part 2: Immunohistochemistry Test Performance CharacteristicsEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 7, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 1: Fit-for-Purpose Approach to Classification of Clinical Immunohistochemistry BiomarkersCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|February 11, 2017
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine. Part 3: Technical Validation of Immunohistochemistry (IHC) Assays in Clinical IHC LaboratoriesEmina E Torlakovic, Carol C Cheung, Corrado D'Arrigo, et al.
Applied Immunohistochemistry & Molecular Morphology : AIMM|December 13, 2016
Evolution of Quality Assurance for Clinical Immunohistochemistry in the Era of Precision Medicine: Part 4: Tissue Tools for Quality Assurance in ImmunohistochemistryCarol C Cheung, Corrado D'Arrigo, Manfred Dietel, et al.
Journal of Medicinal Chemistry|April 14, 2009
8-(4-Methoxyphenyl)pyrazolo[1,5-a]-1,3,5-triazines: selective and centrally active corticotropin-releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Liqi He, Todd Clarke, et al.
Journal of Medicinal Chemistry|April 14, 2009
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonistsPaul J Gilligan, Todd Clarke, Liqi He, et al.
Ebiomedicine|September 13, 2025
New standards in HER2-low testing: the CASI-01 comparative methods studyDavid J Dabbs, Emina Torlakovic, Søren Nielsen, et al.
American Journal of Cancer Research|September 2, 2015
Monosomy of chromosome 17 in breast cancer during interpretation of HER2 gene amplificationMatteo Brunelli, Alessia Nottegar, Giuseppe Bogina, et al.
Pageof 16